



EUropean Group On Graves Orbitopathy

# SATELLITE SYMPOSIUM

4th September 2026,

Porto, Portugal



# Satellite Symposium - EUGOGO 2026

## 04. September 2026 Porto, Portugal

**Venue**            **Alfandega Congress Center**  
Rua Nova da Alfândega  
Edifício da Alfândega  
4050-430 Porto, Portugal

**Registration:** <https://www.m-anage.com/Login.aspx?event=eugogo2026>

### **Registration (Deadline: 26.08.2026)**

Participant            150,00 €  
Industry                600,00 €

Payment Methods:    By credit card

The registration fee includes coffee breaks, lunch, participation in the scientific program and entrance to the exhibition area.

### **Scientific Chairs**

#### **Maria-Cristina Burlacu (EUGOGO)**

Education/Website/ Communications Lead, Cliniques Universitaires Saint-Luc Brussel, Belgium

#### **Tomasz Bednarczyk (ETA)**

Medical University of Warsaw, Warsaw, Poland

#### **Simon Pearce (ETA)**

Translational and Clinical Research Institute, Newcastle University, UK

### **Executive Committee EUGOGO**

#### **Mario Salvi**

President, University of Milan Fondazione Ospedale Policlinico  
istituto di ricovero e Cura a Carattere Scientifico, Italy

#### **Vickie Lee**

Secretary, Imperial College London, Western Eye Hospital, United Kingdom

#### **Nicole Fichter**

Treasurer, Admedico Orbital Centre Olten, Switzerland

#### **Colin Dayan**

Guidelines Lead, University Birmingham, United Kingdom

#### **Anja Eckstein**

Observational/Interventional/ Research Studies Lead, Head of Orbital Center,  
Department of Ophthalmology, University Medicine Essen, Germany

#### **Ilaria Muller**

Basic Sciences Studies Lead University of Milan Fondazione Ospedale  
Policlinico istituto di ricovero e Cura a Carattere Scientifico, Italy

#### **Maria-Cristina Burlacu**

Education/Website/ Communications Lead, Cliniques Universitaires Saint-Luc Brussel, Belgium

Friday, 4th September 2026

## **A Patient-Centric Approach to Thyroid Eye Disease management - 2026**

9:00 - 9:05 h            **Welcome**  
*Mario Salvi*

**Session 1:    Diagnosis**  
*Chairs : Anja Eckstein / Marius Stan*

9:05 - 9:20 h            Pitfalls in recognising TED in clinical practice  
*Vickie Lee , London, UK*

9:20 - 9:35 h            Assessing TED activity beyond Clinical Activity Score  
*Anja Eckstein, Essen, Germany*

9:35 - 9:50 h            Assessing TED severity beyond EUGOGO classification  
*Tomasz Bednarczuk , Warsaw, Poland*

9:50 - 10:10 h            Recognising Dysthyroid Optic Neuropathy (DON)  
-recognising DON by the endocrinologist  
*Milos Zarkovic, Belgrad, Serbia*  
- investigating DON by the ophthalmologist  
*Marco Salez, Madrid, Spain*

10:10 - 10:40 h            Discussion

**10:40 - 11:15 h            Coffee break**

**Session 2:    Prevention**  
*Chairs: Simon Pearce / Vickie Lee*

11:15 - 11:30 h            Statins for TED prevention and treatment  
*Michele Marino, Pisa, Italy*

11:30 - 11:45 h            Which treatment for hyperthyroidism for which patient?  
*Camille Buffet, Paris, France*

11:45 - 12:00 h            Targeting TSH receptor antibodies in Graves' disease and TED  
*Marius Stan, Mayo Clinic, USA*

12:00 - 12:30 h            Discussion

**12:30-13:30 h            Lunch**

**Session 3: Systemic treatments for TED**

*Chairs: Mario Salvi/ Chrysoula Dosiou*

- 13:30 - 13:45 h Oldies but goldies: steroids for active TED  
*Maria-Cristina Burlacu , Brussels, Belgium*
- 13:45 - 14:00 h Biologics for active TED  
*Ilaria Muller, Milano, Italy*
- 14:00 - 14:15 h The good and the bad of IGF1R blockade for active TED  
*Chrysoula Dosiou , Stanford, USA*
- 14:15 - 14:30 h Is 1 + 1 always 2? Combined treatments for TED  
*Simon Pearce, Newcastle, UK*
- 14:30 - 14:45 h Safety first - Adverse events of the new targeted therapies  
*Marius Stan, Mayo Clinic, USA*
- 14:45 - 15:00 h Personalized therapy in TED - the best use of all available treatments  
*Juliette Abeillon-du Payrat , Lyon, France*
- 15:00 - 15:15 h What can surgery add to TED treatment?  
*Marco Salez, Madrid, Spain*
- 15:15 - 15:45 h Discussion
- 15:45 - 16:15 h Coffee break**

**Session 4: Quality of Life matters - special ophthalmological considerations**

*Chairs: Tomasz Bednarczuk / Antonio Manuel Garrido Hermosilla*

- 16:15 - 16:30 h Management of Dry Eye Syndrome in TED beyond lubricants  
*Vickie Lee, London, UK*
- 16:30 - 16:45 h Management of lid retraction and lagophthalmos in active and chronic TED  
*Antonio Manuel Garrido Hermosilla, Sevilla, Spain*
- 16:45 - 17:00 h When and how quickly to refer to ophthalmologist  
(including ophthalmic emergencies) – the role of combined clinic  
*Claire Feeney, London, UK*
- 17:00 - 17:30 h Discussion
- 17:30 h End of the day**

## **General Information**

### **Accreditation**

The Symposium will be submitted for EACCME® accreditation.

An equivalent Certificate of Attendance will be provided after the event.

### **Accommodation**

Please note that no hotel rooms are reserved. Accommodation should be booked individually via the usual hotel booking platforms.

### **Official Language**

English

### **Travel Information**

#### **By Air**

Porto is served by Francisco Sá Carneiro Airport (OPO) with numerous international connections.

From the Airport to the Congress Venue

The Alfândega Porto Congress Centre can be reached from the airport in approximately 25–30 minutes by taxi or ride-sharing services.

The city centre is also easily accessible by metro and public transport.

#### **By Train**

Porto is well connected by train. The main stations Campanhã and São Bento offer frequent national and international connections. From the city centre, the congress venue can be reached by public transport or taxi.

### **Congress Organization**

Endoscience Endokrinologie Service GmbH

Hopfengartenweg 19

90518 Altdorf

Contacts:

Registration: Susanne Rothe  
[rothe@endoscience.de](mailto:rothe@endoscience.de)

Sponsoring: Yvonne Brunotte  
[brunotte@endoscience.de](mailto:brunotte@endoscience.de)

## Sponsors

The organizers gratefully acknowledge the support of the following sponsors:



The sponsors had no influence on the scientific program or educational content.